Home/Filings/4/0000950170-25-081041
4//SEC Filing

Easom Eric 4

Accession 0000950170-25-081041

CIK 0001880438other

Filed

Jun 2, 8:00 PM ET

Accepted

Jun 3, 4:46 PM ET

Size

8.0 KB

Accession

0000950170-25-081041

Insider Transaction Report

Form 4
Period: 2025-06-02
Easom Eric
DirectorChief Executive Officer
Transactions
  • Purchase

    Common Stock

    2025-06-02$1.07/sh+10,000$10,665256,380 total
Holdings
  • Common Stock

    (indirect: See Footnote)
    1,065,766
  • Common Stock

    (indirect: See Footnote)
    97,058
  • Common Stock

    (indirect: See Footnote)
    97,058
Footnotes (5)
  • [F1]This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.05 to $1.0699 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
  • [F2]Includes (i) 145,250 restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date and (ii) a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
  • [F3]Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
  • [F4]Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
  • [F5]Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.

Documents

1 file

Issuer

AN2 Therapeutics, Inc.

CIK 0001880438

Entity typeother

Related Parties

1
  • filerCIK 0001914503

Filing Metadata

Form type
4
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 4:46 PM ET
Size
8.0 KB